CA2585640C - Use of 2-o desulfated heparin for the treatment of heparin-induced thrombocytopenia (hit) syndrome - Google Patents

Use of 2-o desulfated heparin for the treatment of heparin-induced thrombocytopenia (hit) syndrome Download PDF

Info

Publication number
CA2585640C
CA2585640C CA2585640A CA2585640A CA2585640C CA 2585640 C CA2585640 C CA 2585640C CA 2585640 A CA2585640 A CA 2585640A CA 2585640 A CA2585640 A CA 2585640A CA 2585640 C CA2585640 C CA 2585640C
Authority
CA
Canada
Prior art keywords
heparin
desulfated
medicament
desulfated heparin
hit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2585640A
Other languages
English (en)
French (fr)
Other versions
CA2585640A1 (en
Inventor
Jeanine M. Walenga
Thomas Preston Kennedy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantex Pharmaceuticals Inc
Original Assignee
ParinGenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ParinGenix Inc filed Critical ParinGenix Inc
Publication of CA2585640A1 publication Critical patent/CA2585640A1/en
Application granted granted Critical
Publication of CA2585640C publication Critical patent/CA2585640C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/10—Heparin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
CA2585640A 2004-10-27 2005-10-26 Use of 2-o desulfated heparin for the treatment of heparin-induced thrombocytopenia (hit) syndrome Expired - Lifetime CA2585640C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/974,566 US7468358B2 (en) 2004-06-16 2004-10-27 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US10/974,566 2004-10-27
PCT/US2005/039011 WO2006047755A2 (en) 2004-10-27 2005-10-26 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome

Publications (2)

Publication Number Publication Date
CA2585640A1 CA2585640A1 (en) 2006-05-04
CA2585640C true CA2585640C (en) 2012-01-10

Family

ID=36228513

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2585640A Expired - Lifetime CA2585640C (en) 2004-10-27 2005-10-26 Use of 2-o desulfated heparin for the treatment of heparin-induced thrombocytopenia (hit) syndrome

Country Status (9)

Country Link
US (1) US7468358B2 (enExample)
EP (1) EP1807095B1 (enExample)
JP (1) JP2008518090A (enExample)
AT (1) ATE507836T1 (enExample)
AU (1) AU2005299568A1 (enExample)
CA (1) CA2585640C (enExample)
DE (1) DE602005027883D1 (enExample)
ES (1) ES2366342T3 (enExample)
WO (1) WO2006047755A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261241A1 (en) 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20090054374A1 (en) * 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
WO2009015183A1 (en) * 2007-07-23 2009-01-29 University Of Utah Research Foundation Method for blocking ligation of the receptor for advanced glycation end-products (rage)
WO2009117677A2 (en) * 2008-03-21 2009-09-24 University Of Utah Research Foundation Methods for controlling intracellular calcium levels associated with an ischemic event
US8288515B2 (en) 2009-07-31 2012-10-16 Reliable Biopharmaceutical Corporation Process for preparing Fondaparinux sodium and intermediates useful in the synthesis thereof
US8420790B2 (en) 2009-10-30 2013-04-16 Reliable Biopharmaceutical Corporation Efficient and scalable process for the manufacture of Fondaparinux sodium
DK3144325T3 (da) * 2010-09-14 2021-01-25 Univ Miyazaki Heparin med høj renhed og fremstillingsfremgangsmåde dertil
NZ611316A (en) * 2010-12-01 2014-12-24 Univ Australian Histone inhibition
WO2013016181A1 (en) * 2011-07-22 2013-01-31 Paringenix, Inc. Compositions and methods for anti-coagulation
CA2862606C (en) 2012-02-02 2020-08-25 Reliable Biopharmaceutical Corporation An efficient and scalable process for the manufacture of fondaparinux sodium
LT2846809T (lt) * 2012-05-09 2021-01-25 Cantex Pharmaceuticals, Inc. Mielosupresijos gydymas
AU2016234916A1 (en) * 2012-05-09 2016-11-17 Cantex Pharmaceuticals, Inc. Treatment of myelosuppression
US20170096549A1 (en) 2014-03-17 2017-04-06 Cantex Pharmaceuticals, Inc. Multivalent cation formulations of partially desulfated heparins
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
EP3265828B1 (en) 2015-03-03 2021-04-21 Laboratory Corporation of America Holdings Methods and systems for measuring serotonin in a sample
WO2019236453A1 (en) * 2018-06-03 2019-12-12 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and /or chemotherapy
WO2022015794A1 (en) 2020-07-14 2022-01-20 Optimvia, Llc Methods for synthesizing non-anticoagulant heparan sulfate
GB202006960D0 (en) * 2020-05-12 2020-06-24 Aplagon Oy Therapeutic

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
EP0651645B1 (en) * 1992-07-24 2002-02-27 Thomas P. Kennedy Medicament for inhibiting neutrophil elastase and cathepsin g
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
US5990097A (en) * 1996-07-29 1999-11-23 Cavalier Pharmaceuticals Methods of treating asthma with o-desulfated heparin
DE69930419T2 (de) 1998-11-13 2006-09-07 Eli Lilly And Co., Indianapolis Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
AU763042B2 (en) 1999-09-13 2003-07-10 Charlotte-Mecklenburg Hospital Authority Method of inhibiting NF-kappaB with heparin
US6489311B1 (en) 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
US20080207895A1 (en) 2002-11-27 2008-08-28 Rosenberg Robert D Methods for synthesizing polysaccharides
US20050261241A1 (en) * 2004-05-19 2005-11-24 Celsus Biopharmaceuticals, Inc. Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses
US20050282775A1 (en) 2004-06-16 2005-12-22 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome

Also Published As

Publication number Publication date
CA2585640A1 (en) 2006-05-04
ATE507836T1 (de) 2011-05-15
EP1807095A2 (en) 2007-07-18
EP1807095B1 (en) 2011-05-04
WO2006047755A2 (en) 2006-05-04
ES2366342T3 (es) 2011-10-19
JP2008518090A (ja) 2008-05-29
WO2006047755A3 (en) 2007-02-01
DE602005027883D1 (de) 2011-06-16
EP1807095A4 (en) 2008-08-27
US7468358B2 (en) 2008-12-23
AU2005299568A1 (en) 2006-05-04
US20070123489A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
CA2585640C (en) Use of 2-o desulfated heparin for the treatment of heparin-induced thrombocytopenia (hit) syndrome
US20050282775A1 (en) Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome
US20060040896A1 (en) Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US5280016A (en) Non-anticoagulant heparin derivatives
Tyrrell et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation
EP2794666B1 (en) Use of chemically modified heparin derivates in sickle cell disease
CA2107365A1 (en) New non-anticoagulant heparin derivatives
WO1996024362A1 (en) Antiinflammatory agents
Thomas et al. A low molecular weight heparin compared with unfractionated heparin
JP2011121955A (ja) ヘパリン様化合物、その製造並びに血管傷害および介入に伴う動脈血栓を阻止するための使用
JP2010534672A (ja) 終末糖化産物受容体（ｒａｇｅ）の連結を阻止するための方法
RU2153506C2 (ru) Дерматансульфат или его соль, противотромбозные средства, способ предупреждения или лечения тромбозов, способ предупреждения или лечения синдрома рассеянной интраваскулярной коагуляции, способ лечения инфаркта миокарда
AU694177B2 (en) Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
Patel et al. Low-molecular-weight heparin (LMWH)–loaded large porous PEG-PLGA particles for the treatment of asthma
EP1300153A1 (en) Use of n-desulfated heparin for treating or preventing inflammations
JPH08277224A (ja) 抗炎症剤
AU763042B2 (en) Method of inhibiting NF-kappaB with heparin
US5981509A (en) Preparation for prophylaxis or treatment of renal diseases containing sulfated polysaccharide
Szczubialka et al. Heparin-a key drug in the treatment of the circulatory degenerative diseases: controlling its action with polymers
JP2018524067A (ja) アンチトロンビン−ヘパリン組成物を利用する医療機器、システムおよび方法
JPH08301771A (ja) 腎疾患の予防または治療用製剤
HK1199893B (en) Use of chemically modified heparin derivates in sickle cell disease

Legal Events

Date Code Title Description
EEER Examination request